Literature DB >> 16644755

111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.

Vladimir Tolmachev1, Fredrik Y Nilsson, Charles Widström, Karl Andersson, Daniel Rosik, Lars Gedda, Anders Wennborg, Anna Orlova.   

Abstract

UNLABELLED: Data on expression of the HER2 (erbB-2) receptor in breast carcinoma make it possible to select the most efficient treatment. There are strong indications that HER2 expression possesses prognostic and predictive values in ovarian, prostate, and lung carcinomas as well. Visualization of HER2 expression using radionuclide targeting can provide important diagnostic information. The Affibody Z(HER2:342) is a short (approximately 7 kDa) phage-display-selected protein that binds HER2 with an affinity of 22 pmol/L. The goal of this study was to evaluate whether (111)In-labeled HER2:342 can be used for imaging of HER2 overexpression in vivo.
METHODS: Z(HER2:342) was labeled with (111)In via isothiocyanate-benzyl-DTPA (DTPA is diethylenetriaminepentaacetic acid) and the conjugate was characterized in vitro and in vivo.
RESULTS: (111)In-Benzyl-DTPA-Z(HER2:342) preserved the capacity to bind living HER2-expressing cells specifically. The affinity of In-benzyl-DTPA-Z(HER2:342) to HER2 was 21 pmol/L according to surface plasmon resonance measurements. In nude mice bearing HER2-expressing SKOV-3 xenografts, a tumor uptake of 12% +/- 3% injected activity per gram and a tumor-to-blood ratio of about 100 were obtained 4 h after injection. Tumor uptake in vivo was receptor specific, as it could be blocked with an excess of nonlabeled Z(HER2:342). HER2-expressing xenografts were clearly imaged 4 h after injection using a gamma-camera.
CONCLUSION: (111)In-Benzyl-DTPA-Z(HER2:342) is a promising candidate for visualization of HER2 expression in carcinomas, using the single-photon detection technique.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644755

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  43 in total

Review 1.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

2.  Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.

Authors:  Victor Chernomordik; Moinuddin Hassan; Sang Bong Lee; Rafal Zielinski; Amir Gandjbakhche; Jacek Capala
Journal:  Mol Imaging       Date:  2010-08       Impact factor: 4.488

3.  Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.

Authors:  Vladimir Tolmachev; Heng Xu; Helena Wållberg; Sara Ahlgren; Magnus Hjertman; Anna Sjöberg; Mattias Sandström; Lars Abrahmsén; Martin W Brechbiel; Anna Orlova
Journal:  Bioconjug Chem       Date:  2008-07-12       Impact factor: 4.774

4.  Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.

Authors:  Torun Ekblad; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsén; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-02       Impact factor: 9.236

Review 5.  Protein scaffold-based molecular probes for cancer molecular imaging.

Authors:  Zheng Miao; Jelena Levi; Zhen Cheng
Journal:  Amino Acids       Date:  2010-02-21       Impact factor: 3.520

6.  In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.

Authors:  Gang Ren; Jack M Webster; Zhe Liu; Rong Zhang; Zheng Miao; Hongguang Liu; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng
Journal:  Amino Acids       Date:  2011-10-08       Impact factor: 3.520

7.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

8.  64Cu-labeled affibody molecules for imaging of HER2 expressing tumors.

Authors:  Zhen Cheng; Omayra Padilla De Jesus; Daniel J Kramer; Abhijit De; Jack M Webster; Olivier Gheysens; Jelena Levi; Mohammad Namavari; Sen Wang; Jinha Mark Park; Rong Zhang; Hongguang Liu; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2009-09-25       Impact factor: 3.488

9.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

10.  HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Authors:  Ilya Lyakhov; Rafal Zielinski; Monika Kuban; Gabriela Kramer-Marek; Robert Fisher; Oleg Chertov; Lakshman Bindu; Jacek Capala
Journal:  Chembiochem       Date:  2010-02-15       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.